19 Jan 2018 13:22 IST

Biocon hits two-week high on Sandoz deal

Up to Thursday's close, the stock had gained 63.2 per cent this year

Shares of Biocon hit near 2-week high as the company has tied up with Sandoz to develop, manufacture and commercialise biosimilars in immunology and oncology for global markets.

The stock jumped as much as 3.9 per cent to ₹560.35, its highest since January 8. Citi Research has raised the stock's price target to ₹ 690 from ₹525. It has maintained “buy” rating.

Biocon will have multiple benefits from the deal, including wider pipeline, greater front-end muscle in developed markets and potentially better acceptance with developing market regulators.

Up to Thursday's close, the stock had gained 63.2 per cent this year.

Videos

Can India become a $5-trillion economy by 2025?

What is RCEP and why did India stay out of it?

'Recruiters want students with good domain knowledge'

Recommended for you